In addition to lorvotuzumab mertansine, IMGN388, T-DM1, and SAR3419, disclosed compounds include:

• BT-062 – This TAP compound is in Phase I clinical testing by our collaborator, Biotest, for the treatment of multiple myeloma. The first clinical data were presented at a medical meeting in December 2009. ImmunoGen has certain opt-in rights for the US.

• BIIB015 – This Cripto-targeting TAP compound is in Phase I clinical testing by our collaborator, Biogen Idec, for the treatment of solid tumors. The first BIIB015 clinical data potentially will be reported in 2010.

• SAR650984 - This therapeutic, or "naked", antibody was advanced into Phase I testing in June 2010 by our collaborator, sanofi-aventis. SAR650984 is a promising treatment for a number of hematological malignancies. In preclinical testing, it achieved notable activity through multiple mechanisms of action. ImmunoGen has deep and established antibody capabilities and we develop both TAP compounds and naked antibody therapeutics.

• SAR566658 - This TAP compound is in development by our collaborator, sanofi-aventis, for the treatment of breast and ovarian cancers and other solid tumors. It has shown encouraging findings in preclinical testing and is advancing towards the clinic.

ImmunoGen has a number of earlier-stage compounds in our preclinical pipeline and we expect to start unveiling our most advanced ones later this year. Additionally, our collaborators Amgen, Bayer HealthCare, Genentech (a member of the Roche Group), and sanofi-aventis have rights to develop compounds additional to the ones listed above.

Back to Pipeline